Phase 2 Medical Device Manufacturing of New Hampshire was in a tough place. Their largest client by far, a biotechnology conglomerate, seemed on the verge of cutting all business with Phase 2 in favor of overseas competition. Faced with such a risk, Phase 2 stepped into action. They promised that they would find a way to match the overseas competitors' prices - which they found would require tripling capacity with minimal added development costs. The solution to that involved a two-part change strategy, combining elements of reducing costs and creating lean Cell Operating Systems that could support the new demands.
In this video, Phase 2 president Adam Prime shares some insider info on his organization's lean journey to reach their goals, as well as the impact it had on both him and his company.